New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Leukemia & Lymphoma
Natali PflugG Hopfinger

Abstract

Clinical trials in T-cell prolymphocytic leukemia (T-PLL) are scarce. Based on a precursor study testing fludarabine, mitoxantrone, and cyclophosphamide followed by alemtuzumab (FMC-A), we aimed to improve this regimen by upfront combining subcutaneous (s.c.) alemtuzumab with FMC for four cycles followed by an alemtuzumab-maintenance (FMCA + A). This prospective multicenter phase-II trial assessed response, survival, and toxicity of that regimen administered to pretreated (n = 4) and treatment-naïve (n = 12) T-PLL patients. The best overall response rate after FMCA was 68.8% (n = 11) including five CRs (31.3%) and six PRs (37.5%). Six patients entered the alemtuzumab-maintenance. Median overall and progression-free survival was 16.7 and 11.2 months, respectively. Hematologic toxicities were the most frequent grade 3/4 side effects. A reduced incidence of CMV-reactivations was attributed to the prophylactic administration of valganciclovir. Overall, FMCA + A did not improve the efficacy of the FMC-A-regimen or of single i.v. alemtuzumab. It suggests that a chemotherapy backbone prevents efficient alemtuzumab dosing and confirms that intravenous alemtuzumab is to be preferred over its s.c. route in T-PLL. ClinicalTrials.gov ident...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J MerciecaD Catovsky
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ExtermannL Balducci
Dec 16, 2005·Clinical Lymphoma & Myeloma·Farhad RavandiMichael Keating
Apr 5, 2007·Cancer Chemotherapy and Pharmacology·Jong Gwang KimSuk Joong Oh
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Varsha GandhiMichael J Keating
Jun 1, 2012·Blood·Claire Dearden
Apr 18, 2013·Annals of Hematology·Francesco ZajaRenato Fanin
Oct 16, 2014·British Journal of Haematology·Charles HerbauxLoïc Ysebaert
Jun 26, 2015·Science Translational Medicine·Zainul S HasanaliElliot M Epner
Oct 1, 2015·Clinical Lymphoma, Myeloma & Leukemia·Moussab DamlajMrinal M Patnaik
Feb 15, 2017·American Journal of Hematology·Zhihong HuXinyan Lu

❮ Previous
Next ❯

Citations

Jan 23, 2019·Leukemia & Lymphoma·Amit Khot
Feb 9, 2020·Current Hematologic Malignancy Reports·Till BraunMarco Herling
Jul 1, 2020·European Endocrinology·Saptarshi BhattacharyaSanjay Kalra

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.